Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385705883> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W4385705883 endingPage "e72049bc" @default.
- W4385705883 startingPage "e72049bc" @default.
- W4385705883 abstract "Topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research Background: Multiple myeloma (MM) is a cancer of plasma cells that occurs in the bone marrow (BM). Despite the recent advancements in drug development for MM, most patients eventually relapse and there is a constant need for developing new therapeutic options for this disease. RNA-based therapies are an appealing therapeutic approach for cancer, as they hold the potential to manipulate the genetic expression of any gene and cell. However, clinical implementation of RNA therapy is limited due to inefficient systemic delivery of ribonucleotides to cells outside the liver, especially lymphocytes. Aims: We aim to generate a novel RNA-based therapy for MM by silencing the expression of crucial genes in MM cells and therefore lead to the alleviation of the disease. Methods: We utilize lipid nanoparticles (LNPs) as they are currently the most advanced and clinically approved non-viral delivery system of RNA. In this study, we present targeted (t)LNPs designed for delivery of RNA payload to MM cells. The tLNPs consists of a novel ionizable lipid and are coated with an anti-CD38 antibody (αCD38-tLNPs). To explore their therapeutic potential, we use small interference RNA (siRNA) to block the expression of cytoskeleton-associated protein 5 (CKAP5), a protein that regulates centrosomal organization during mitosis. Results: We demonstrate that LNPs encapsulating siRNA-CKAP5 lead to a significant decrease in cell viability upon transfection of MM cells in vitro and primary MM cells ex vivo. Next, since previously described xenograft MM mouse models have poor homing of MM cells to the BM and are therefore not suitable for evaluating the retention of systemically administered drugs to the BM, we establish a novel xenograft MM mouse model. Our new model clinically resembles the human disease as the MM-bearing mice display lytic bone lesion and secretion of monoclonal protein to the serum, and, importantly, demonstrate efficient homing of MM cells to the BM. Using this model, we show the specific delivery of αCD38-tLNPs to BM-residing and disseminated MM cells and the improvement in therapeutic outcome of MM-bearing mice treated with αCD38-tLNPs-siRNA-CKAP5. Summary/Conclusion: These results underscore the potential of RNA therapeutics for the treatment of MM and the importance of developing effective targeted delivery systems and reliable preclinical models.Keywords: Nanoparticle, Multiple myeloma, RNA interference (RNAi), Bone Marrow" @default.
- W4385705883 created "2023-08-10" @default.
- W4385705883 creator A5009782479 @default.
- W4385705883 creator A5010882590 @default.
- W4385705883 creator A5036139479 @default.
- W4385705883 creator A5038855686 @default.
- W4385705883 creator A5054545367 @default.
- W4385705883 creator A5086557065 @default.
- W4385705883 date "2023-08-01" @default.
- W4385705883 modified "2023-09-27" @default.
- W4385705883 title "P1355: DELIVERY OF THERAPEUTIC RNA TO THE BONE MARROW IN MULTIPLE MYELOMA USING CD38-TARGETED LIPID NANOPARTICLES" @default.
- W4385705883 doi "https://doi.org/10.1097/01.hs9.0000972308.72049.bc" @default.
- W4385705883 hasPublicationYear "2023" @default.
- W4385705883 type Work @default.
- W4385705883 citedByCount "0" @default.
- W4385705883 crossrefType "journal-article" @default.
- W4385705883 hasAuthorship W4385705883A5009782479 @default.
- W4385705883 hasAuthorship W4385705883A5010882590 @default.
- W4385705883 hasAuthorship W4385705883A5036139479 @default.
- W4385705883 hasAuthorship W4385705883A5038855686 @default.
- W4385705883 hasAuthorship W4385705883A5054545367 @default.
- W4385705883 hasAuthorship W4385705883A5086557065 @default.
- W4385705883 hasBestOaLocation W43857058831 @default.
- W4385705883 hasConcept C10205521 @default.
- W4385705883 hasConcept C104317684 @default.
- W4385705883 hasConcept C111599444 @default.
- W4385705883 hasConcept C119056186 @default.
- W4385705883 hasConcept C121608353 @default.
- W4385705883 hasConcept C126322002 @default.
- W4385705883 hasConcept C150903083 @default.
- W4385705883 hasConcept C159912055 @default.
- W4385705883 hasConcept C166703698 @default.
- W4385705883 hasConcept C203014093 @default.
- W4385705883 hasConcept C207001950 @default.
- W4385705883 hasConcept C22615655 @default.
- W4385705883 hasConcept C26291073 @default.
- W4385705883 hasConcept C2776364478 @default.
- W4385705883 hasConcept C2777478702 @default.
- W4385705883 hasConcept C2780007613 @default.
- W4385705883 hasConcept C2781119759 @default.
- W4385705883 hasConcept C28328180 @default.
- W4385705883 hasConcept C502942594 @default.
- W4385705883 hasConcept C54009773 @default.
- W4385705883 hasConcept C54355233 @default.
- W4385705883 hasConcept C55493867 @default.
- W4385705883 hasConcept C67705224 @default.
- W4385705883 hasConcept C71924100 @default.
- W4385705883 hasConcept C81885089 @default.
- W4385705883 hasConcept C86803240 @default.
- W4385705883 hasConcept C95444343 @default.
- W4385705883 hasConcept C96232424 @default.
- W4385705883 hasConceptScore W4385705883C10205521 @default.
- W4385705883 hasConceptScore W4385705883C104317684 @default.
- W4385705883 hasConceptScore W4385705883C111599444 @default.
- W4385705883 hasConceptScore W4385705883C119056186 @default.
- W4385705883 hasConceptScore W4385705883C121608353 @default.
- W4385705883 hasConceptScore W4385705883C126322002 @default.
- W4385705883 hasConceptScore W4385705883C150903083 @default.
- W4385705883 hasConceptScore W4385705883C159912055 @default.
- W4385705883 hasConceptScore W4385705883C166703698 @default.
- W4385705883 hasConceptScore W4385705883C203014093 @default.
- W4385705883 hasConceptScore W4385705883C207001950 @default.
- W4385705883 hasConceptScore W4385705883C22615655 @default.
- W4385705883 hasConceptScore W4385705883C26291073 @default.
- W4385705883 hasConceptScore W4385705883C2776364478 @default.
- W4385705883 hasConceptScore W4385705883C2777478702 @default.
- W4385705883 hasConceptScore W4385705883C2780007613 @default.
- W4385705883 hasConceptScore W4385705883C2781119759 @default.
- W4385705883 hasConceptScore W4385705883C28328180 @default.
- W4385705883 hasConceptScore W4385705883C502942594 @default.
- W4385705883 hasConceptScore W4385705883C54009773 @default.
- W4385705883 hasConceptScore W4385705883C54355233 @default.
- W4385705883 hasConceptScore W4385705883C55493867 @default.
- W4385705883 hasConceptScore W4385705883C67705224 @default.
- W4385705883 hasConceptScore W4385705883C71924100 @default.
- W4385705883 hasConceptScore W4385705883C81885089 @default.
- W4385705883 hasConceptScore W4385705883C86803240 @default.
- W4385705883 hasConceptScore W4385705883C95444343 @default.
- W4385705883 hasConceptScore W4385705883C96232424 @default.
- W4385705883 hasIssue "S3" @default.
- W4385705883 hasLocation W43857058831 @default.
- W4385705883 hasLocation W43857058832 @default.
- W4385705883 hasOpenAccess W4385705883 @default.
- W4385705883 hasPrimaryLocation W43857058831 @default.
- W4385705883 hasRelatedWork W1977455975 @default.
- W4385705883 hasRelatedWork W2017150004 @default.
- W4385705883 hasRelatedWork W2062595050 @default.
- W4385705883 hasRelatedWork W2155858875 @default.
- W4385705883 hasRelatedWork W2231560277 @default.
- W4385705883 hasRelatedWork W2308340008 @default.
- W4385705883 hasRelatedWork W2353794636 @default.
- W4385705883 hasRelatedWork W2355944007 @default.
- W4385705883 hasRelatedWork W2383161240 @default.
- W4385705883 hasRelatedWork W2438003748 @default.
- W4385705883 hasVolume "7" @default.
- W4385705883 isParatext "false" @default.
- W4385705883 isRetracted "false" @default.
- W4385705883 workType "article" @default.